What is a stock summary page? Click here for an overview.
Business Description
Integrated Biopharma Inc
NAICS : 311999
SIC : 5142
ISIN : US45811V1052
Description
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from Contract Manufacturing segment which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.86 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.49 | |||||
| Interest Coverage | 362.25 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.11 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.3 | |||||
| 3-Year EBITDA Growth Rate | -42.9 | |||||
| 3-Year EPS without NRI Growth Rate | -73.4 | |||||
| 3-Year FCF Growth Rate | -46.7 | |||||
| 3-Year Book Growth Rate | 9.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.18 | |||||
| 9-Day RSI | 35.06 | |||||
| 14-Day RSI | 40.61 | |||||
| 3-1 Month Momentum % | -7.77 | |||||
| 6-1 Month Momentum % | 22.94 | |||||
| 12-1 Month Momentum % | 34.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.26 | |||||
| Quick Ratio | 1.27 | |||||
| Cash Ratio | 0.44 | |||||
| Days Inventory | 88.21 | |||||
| Days Sales Outstanding | 30.44 | |||||
| Days Payable | 23.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 8.83 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 9.73 | |||||
| Operating Margin % | 2.78 | |||||
| Net Margin % | 1.78 | |||||
| FCF Margin % | 3.34 | |||||
| ROE % | 4.83 | |||||
| ROA % | 3.55 | |||||
| ROIC % | 4.82 | |||||
| 3-Year ROIIC % | 822.28 | |||||
| ROC (Joel Greenblatt) % | 9.97 | |||||
| ROCE % | 7.23 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.53 | |||||
| PE Ratio without NRI | 8.53 | |||||
| Price-to-Owner-Earnings | 5 | |||||
| PS Ratio | 0.18 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 0.45 | |||||
| Price-to-Free-Cash-Flow | 5.08 | |||||
| Price-to-Operating-Cash-Flow | 3.92 | |||||
| EV-to-EBIT | 5.28 | |||||
| EV-to-EBITDA | 2.82 | |||||
| EV-to-Revenue | 0.15 | |||||
| EV-to-FCF | 5.27 | |||||
| Price-to-GF-Value | 0.88 | |||||
| Price-to-Projected-FCF | 0.31 | |||||
| Price-to-Median-PS-Value | 1.26 | |||||
| Price-to-Graham-Number | 0.41 | |||||
| Price-to-Net-Current-Asset-Value | 0.73 | |||||
| Earnings Yield (Greenblatt) % | 18.94 | |||||
| FCF Yield % | 19.79 | |||||
| Forward Rate of Return (Yacktman) % | -13.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:INBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Integrated Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 52.124 | ||
| EPS (TTM) ($) | 0.034 | ||
| Beta | 0.73 | ||
| 3-Year Sharpe Ratio | -0.57 | ||
| 3-Year Sortino Ratio | -0.76 | ||
| Volatility % | 61.09 | ||
| 14-Day RSI | 40.61 | ||
| 14-Day ATR ($) | 0.01897 | ||
| 20-Day SMA ($) | 0.312915 | ||
| 12-1 Month Momentum % | 34.34 | ||
| 52-Week Range ($) | 0.16375 - 0.42 | ||
| Shares Outstanding (Mil) | 30.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Integrated Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Integrated Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Integrated Biopharma Inc Frequently Asked Questions
What is Integrated Biopharma Inc(INBP)'s stock price today?
The current price of INBP is $0.29. The 52 week high of INBP is $0.42 and 52 week low is $0.16.
When is next earnings date of Integrated Biopharma Inc(INBP)?
The next earnings date of Integrated Biopharma Inc(INBP) is .
Does Integrated Biopharma Inc(INBP) pay dividends? If so, how much?
Integrated Biopharma Inc(INBP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers